Hostname: page-component-848d4c4894-4hhp2 Total loading time: 0 Render date: 2024-06-03T04:05:49.643Z Has data issue: false hasContentIssue false
  • English
  • Français

Beta-Lactamase Inhibitors: Another Approach to Overcoming Antimicrobial Resistance

Published online by Cambridge University Press:  02 January 2015

Richard H. Parker  and
Mark Eggleston
Richard H. Parker
Affiliation:
Howard University School of Medicine, College of Pharmacy & Pharmacal Sciences, Howard University; and the Antimicrobial Agent Research Laboratory, Providence Hospital, Washington, DC
Mark Eggleston*
Affiliation:
Howard University School of Medicine, College of Pharmacy & Pharmacal Sciences, Howard University; and the Antimicrobial Agent Research Laboratory, Providence Hospital, Washington, DC
*
PO Box 115, Woodbridge, VA 22193
Get access Rights & Permissions [Opens in a new window]

Extract

Resistance of most clinical pathogens to beta-lactam antimicrobial agents is currently primarily mediated by the microorganisms' ability to product beta-lactamases. There are a variety of beta-lactamases which are primarily differentiated by whether they are plasmid- or chromosome-mediated and by their substrate and inhibition profiles. The most common group of beta-lactamases produced by clinical isolates are the plasmid-mediated TEM enzymes (Richmond-Sykes type III a) which exist in many Enterobacteriaceae, Hemophilus influenzae, and Neisseria species. Development of new beta-lactam antimicrobial agents during the past decades has resulted in a number of drugs with increased, albeit not total, resistance to beta-lactamases. Another approach has been the development of beta-lactamase inhibitors that can be used with a beta-lactam drug to overcome the resistance created by the beta-lactamase.

Type
Special Sections
Information
Infection Control & Hospital Epidemiology , Volume 8 , Issue 1 , January 1987 , pp. 36 - 40
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1987

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Neu, HC, Fu, KP: Clavulanic acid: A novel inhibitor of beta-lactamases. Antimicrob Agents Chemother 1978; 14:650.Google Scholar
2.Reading, C, Cole, M: Clavulanic acid: A beta-lactamase-inhibiting beta-lactam from Streptomyces clavuligerus. Antimicrob Agents Chemother 1977; 11:852.CrossRefGoogle Scholar
3.Munch, P, Luthy, R, Blaser, J, et al: Human pharmacokinetics and CAF penetration of clavulanic acid. J Antimicrob Chemother 1981; 8:29.Google Scholar
4.Adam, D, Visser, I, Koeppe, P: Pharmacokinetics of amoxicillin and clavulanic acid administered alone and in combination. Antimicrob Agents Chemother 1982; 22:353.Google Scholar
5.Saito, A: The pharmacokinetics BRL-25000—Augmentin in humans, in Leigh, DA, Robinson, DPW (eds): Proceedings of an International Symposium on Augmentin (BRL 25000), Montreux, Switzerland, July 17,1981. Amsterdam, Excerpta Medica 1982; 34–36.Google Scholar
6.Jackson, D, Cooper, DL, Hardy, DL, et al: Pharmacokinetic toxicological and metabolic studies with augmentin, in Rolinon, GN, Watson, A (eds): Augmentin: Proceedings of the First Symposium, July 3-4, 1980. Amsterdam, Excerpta Medica 1980; 87–105.Google Scholar
7.Ball, AP, Geddes, AM, Davey, PG, et al: Clavulanic acid and amoxicillin: A clinical, bacteriological and pharmacological study. Lancet 1980; 1:620–623.Google Scholar
8.Kosmidis, J, Stathkis, C, Kotium, D, et al: Pharmacokinetic studies with augmentin, a combination of amoxicillin and potassium clavulanate, in Proceedings of the 12th International Congress of Chemotherapy. Florence, Italy, 1981.Google Scholar
9.Nelson, JD, Kusmie, SZ, Shelton, S: Pharmacokinetics of potassium clavulanate in combination with amoxicillin in pediatric patients. Antimicrob Agents Chemother 1982; 21:681–682.CrossRefGoogle ScholarPubMed
10.Vanniekerk, CH, Van Den Ende, J, Couw, EA, et al: A pharmacokinetic study of pediatric formulations of amoxicillin plus clavulanic acid (augmentin) in children (Abstract 309), in: Program and Abstracts of the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 1982.Google Scholar
11.Eshelman, FN, Spyker, DA: Pharmacokinetics of amoxicillin and ampicillin: Crossover study of the effect of food. Antimicrob Agents Chemother 1979; 14:539–543.CrossRefGoogle Scholar
12.Staniforth, DH, Lillystone, RJ, Jackson, D: Effect of food on the bioavailability and tolerance of clavulanic acid/amoxicillin combination. J Antimicrob Chemother 1982; 10:131–139.CrossRefGoogle Scholar
13.Neu, HC: Beta-lactamase inhibitors, in Mandell, GL, Douglas, RG, Bennett, JE (eds): Principles and Practice of Infectious Disease, ed 3. New York, John Wiley & Sons, 1985, pp 190–192.Google Scholar
14.Haginaka, J, Nagakawa, T, Nishino, Y, et al: High performance liquid chromatographics determination of clavulanic acid in human urine. J Antibiot 1981; 34:1189–1194.CrossRefGoogle Scholar
15.Reeves, DJ, Elliot, PJ, Holt, HA, et al: A clinical trial of augmentin in urinary tract infections, in Rolison, GN, Watson, A (eds): Augmentin: Proceedings of the First Symposium, July 3-4, 1980. Amsterdam, Excerpta Medica 1980; 133–144.Google Scholar
16.Ball, AP, Farrell, ID, Brookes, GR, et al: Disposition studies of augmentin formulations, in Rounson, GN, Watson, A (eds): Augmentin: Proceedings of the First Symposium, July 3-4, 1980. Amsterdam, Excerpta Medica 1980; 117–121.Google Scholar
17.Hoffler, D, Dalhoff, A: Pharmacokinetics of clavulanic acid in patients with normal and impaired renal function (Abstract 296), in Program and Abstracts of the 19th lnterscience Conference on Antimicrobial Agents and Chemotherapy. Boston, 1979.Google Scholar
18.Harvard, CWH, Fernando, A, Brumfitt, W, et al: A pilot study of augmentin in lower respiratory tract infections: Pharmacokinetic and clinical results. Br J Dis Chest 1982; 76:255–260.Google Scholar
19.Graham, VAL, Lowes, JA, Shaw, EJ, et al: An assessment of the value of augmentin in the management of respiratory tract infections, in Leigh, DA, Robinson, OPW (eds): Proceedings of an International Symposium on Augmentin (BRL 25000), Montreux, Switzerland, July 17, 1981. Amsterdam, Excerpta Medica 1982; 138–148.Google Scholar
20.Kitzis, MD, Kitzis, MV, Yvelin, C, et al: Pharmacokinetics of augmentin in the pleura, in Conference on Anti-Infectious Chemotherapy. Paris, Dec. 3, 1981.Google Scholar
21.Wise, R, Donovan, JA, Drumm, J, et al: The penetration of amoxicillin/clavulanate acid into peritoneal fluid. J Antimicrob Chemother 1983; 11:57–60.CrossRefGoogle Scholar
22.Piccoli, S, Tran, VT: Transfer of augmentin into the cerebrospinal fluid in experimentally induced meningitis in animals and in humans affected by meningitis, in Conference on Anti-Infectious Chemotherapy. Paris, Dec. 3, 1981.Google Scholar
23.Croydon, EAP, Sutherland, A: Tissue penetration of amoxicillin and clavulanic acid following oral augmentin (Abstract 304), in Program and Abstracts of the 22nd lnterscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 1981.Google Scholar
24.Baba, S: Clinical studies on augmentin in the treatment of otorhinolaryngological infection, in Leigh, DA, Robinson, OPW (eds): Proceedings of an International Symposium on Augmentin (BRL 25000), Montreux, Switzerland, July 17, 1981. Amsterdam, Excerpta Medica 1982; 149–155.Google Scholar
25.Matsuda, S: Augmentin treatment in obstetrics and gynecology, in Leigh, DA, Robinson, OPW (eds): Proceedings of an International Symposium on Augmentin (BRL 25000), Montreux, Switzerland, July 17, 1981. Amsterdam, Excerpta Medica 1982; 179–191.Google Scholar
26.Nishiura, T: Efficacy of augmentin (BRL 25000) in urinary tract infections, in Leigh, DA, Robinson, OPW (eds): Proceedings of International Symposium on Augmentin (BRL 25000), Montreux, Switzerland, July 17,1981. Amsterdam, Excerpta Medica 1982; 65–77.Google Scholar
27.Levenstein, JM, Kritzinger, NA: A general practitioner trial on the efficacy and tolerability of augmentin in the treatment of common bacterial infections, in Leigh, DA, Robinson, OPW (eds): Proceedings of an International Symposium on Augmentin (BRL 25000), Montreux, Switzerland, July 17, 1981. Amsterdam, Excerpta Medica 1982; 113–124.Google Scholar
28.Neu, HC: Amoxicillin. Ann Intern Med 1979; 90:356–360.Google Scholar
29.Watson, A, Mahendra, M: A multicentre therapeutic study of augmentin in infections presenting in general practice, in Rolinson, GN, Watson, A (eds): Augmentin: Proceedings of the First Symposium, July 3-4, 1980. Amsterdam, Excerpta Medica 1980; 187–202.Google Scholar
30.Aswapokee, N, Neu, HC: A sulfone, beta-lactam compound which acts as a beta-lactamase inhibitor. J Antibiot 1978; 31:1238.CrossRefGoogle ScholarPubMed
31.Retsema, VA, English, AR, Girard, AE: CP-45, 899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, Haemophilus influenzae and bacteroides. Antimicrob Agents Chemother 1980; 17:615.CrossRefGoogle ScholarPubMed
32.Foulds, G, Stankewich, JP, Marshall, DC, et al: Pharmacokinetics of sulbactam in humans. Antimicrob Agents Chemother 1983; 23:692.CrossRefGoogle ScholarPubMed
33.Goldstein, FW, Kitzis, MD, Acar, JF: Effect of clavulanic acid and amoxicillin formulation against beta-lactamase-producing gram-negative bacteria in urinary tract infections. J Antimicrob Chemother 1979; 5:705.Google Scholar
34.Rubin, RH, Tolkoff-Rubin, NE, Weber, JD: Augmentin in the treatment of urinary tract infection. Postgrad Med 1984; (suppl):79.Google Scholar
35.Madsen, PO, Dorflinger, T, Frimodt-Moller, P: Augmentin and cefaclor in treatment of complicated urinary tract infections: A comparative study. Postgrad Med 1984; (suppl):191.Google Scholar
36.Tan, JS, File, TM Jr: Double-blind efficacy and safety study of augmentin versus cefaclor in the treatment of lower respiratory tract infection. Postgrad Med 1984; (suppl):129.Google Scholar
37.Seidenfeld, JJ: A double-blind trial of amoxicillin and clavulanic acid versus cefaclor in adult patients with lower respiratory tract infection. Postgrad Med 1984; (suppl):177.Google Scholar
38.Gooch, WM III, Congeni, BL, Sweenson, E, et al: Oral augmentin in the management of pediatric pneumonia. Postgrad Med 1984; (suppl):187.Google Scholar
39.Bluestone, CD: Augmentin therapy of acute otitis media in children: Summary of presentations from four clinical trails. Postgrad Med 1984; (suppl):137.Google Scholar
40.Goldstein, EJC, Reinhardt, JR, Murray, PM, et al: Animal and human bite wounds: A comparative study, augmentin vs. penicillin +/− dicloxacillin. Postgrad Med 1984; (suppl):105.Google Scholar
41.Fainstein, V, Elting, L, Pitlik, S, et al: Ticarcillin plus clavulanic acid in the treatment of patients with cancer. Am J Med 1985; 79(suppl 5B):62.Google Scholar
42.Williams, ME, Harman, C, Schel, M, et al: A controlled study: Ticarcillin plus clavulanic acid versus piperacillin as empiric therapy for fever in the immunocompromised host. Am J Med 1985; 79(suppl 5B):67.Google Scholar
43.Mostow, SR, O'Brien, RF: Safety and effectiveness of ticarcillin plus clavulanate potassium in treatment of lower respiratory tract infections. Am J Med 1985; 79(suppl 5B):78.Google Scholar
44.Brittain, DC, Scully, BE, Neu, HC: Ticarcillin plus clavulanic acid in the treatment of pneumonia and other serious infections. Am J Med 1985; 79(suppl 5B):81.Google Scholar
45.File, TM Jr, Tan, JS, Salstron, SJ, et al: Timentin versus piperacillin or moxalactam in the therapy of acute bacterial infections. Antimicrob Agents Chemother 1984; 26(3):310–313.Google Scholar
46.Pankey, GA, Katner, HP, Valainis, GT, et al: Overview of bacterial infections of the skin and soft tissue and clinical experience with ticarcillin plus clavulanate potassium in their treatment. Am J Med 1985; 79(suppl 5B):106.CrossRefGoogle ScholarPubMed
47.LeFrock, JL, Johnson, ES, Smith, LG, et al: Noncomparative trial of ticarcillin plus clavulanic acid in skin and soft tissue infections. Am J Med 1985; 79(suppl 5B):122.Google Scholar
48.Rao, B, See, RC, Chuah, SK, et al: Ticarcillin plus clavulanic acid versus moxalactam in the treatment of skin and soft tissue infections. Am J Med 1985; 79(suppl 5B):126.Google Scholar
49.Gentry, LO, Macko, V, Lind, R, et al: Ticarcillin plus clavulanic acid (timentin) therapy for osteomyelitis. Am J Med 1985; 79(suppl 5B):116.Google Scholar
50.Johnson, CC, Reinhardt, JF, Wallace, SL, et al: Safety and efficacy of ticarcillin plus clavulanic acid in the treatment of infections of soft tissue, bone and joint. Am J Med 1985; 79(suppl 5B):136.Google Scholar
51.Siebert, WT, Koop, PE: Ticarcillin plus clavulanic acid versus moxalactam therapy of osteomyelitis, septic arthritis, and skin and soft tissue infections. Am J Med 1985; 79(suppl 5B):141.Google Scholar
52.Cox, CE: Comparative study of ticarcillin plus clavulanate potassium versus piperacillin in the treatment of hospitalized patients with urinary tract infections. Am J Med 1985; 79(suppl 5B):88.Google Scholar
53.Pastorek, JG Jr, Aldridge, KE, Cunningham, GL, et al: Comparison of ticarcillin plus clavulanic acid with cefoxitin in the treatment of female pelvic infection. Am J Med 1985; 79(suppl 5B):161.CrossRefGoogle ScholarPubMed
54.Fabian, TC, Boldreghini, SJ: Antibiotics in penetrating abdominal trauma. Comparison of ticarcillin plus clavulanic acid with gentamicin plus clindamycin. Am J Med 1985; 79(suppl 5B):157.CrossRefGoogle ScholarPubMed